RNF144A enforces IL-2-STAT5 dominance over RAF-ERK-MAPK signaling in antiviral CD8 T cells 2309113

D Dhaneshwar Kumar E Erin West D Dragana Jankovic S Suman Mitra A Alejandro Villarino (1University of Miami-Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, United States) Z Zu-Xi Yu (National Institutes of Health) M Marie-José Bijlmakers (King’s College London , London,) L Lauren Brinster (5Division of Veterinary Resources, Office of Research Services, NIH, Bethesda, United States) D Daniel Chauss (NIH) N Nardos Cheru (National Institutes of Health) T Tilo Freiwald (Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany) S Sangmi Kim (King’s College London , London,) N Nicolas Merle (NHLBI/NIH) H Hiroyuki Nagashima E Estefania Nova-Lamperti (King’s College London, London, UK) B Bingyu Yan (Stanford University) G Gregory Weitsman (King’s College London , London,) C Claudia Kemper (NIH) A Arian Laurence (4UCL Hospitals NHS Trust, London, United Kingdom, London, United Kingdom) M Majid Kazemian J John O’Shea B Behdad Afzali S Susan John

Abstract

Abstract Introduction IL-2 is central to CD8 T cell responses and signals via JAK-STAT5, RAF-ERK-MAPK, and PI3K-AKT pathways, but how STAT5-dominant output is enforced from this shared receptor is unclear. We hypothesized that uncharacterized IL-2-induced, STAT5-regulated E3 ubiquitin ligases sculpt this signaling hierarchy to optimize antiviral CD8 T cell function. Methods RNA-seq of human CD8 T cells stimulated with IL-2 ± JAK inhibition plus STAT5 ChIP-seq identified IL-2/STAT5-regulated ubiquitin genes. Rnf144a-/- mice and mixed bone marrow chimeras were used to define CD8-intrinsic roles during influenza infection. RNF144A localization and substrates were mapped by biochemical and imaging assays, and whole-blood transcriptomes from patients with moderate or severe influenza were analyzed to relate RNF144A expression and gene signatures to clinical severity. Results IL-2 broadly remodeled the T cell ubiquitin program, with RNF144A emerging as the most strongly induced STAT5-bound E3 ligase. RNF144A localized to the plasma membrane, associated with IL-2Rβ and STAT5, and enhanced STAT5 recruitment and phosphorylation, sustaining STAT5-dependent transcription. In parallel, RNF144A acted as a bona fide E3 ligase that directly polyubiquitinated RAF1 for degradation, reducing ERK activation and thereby preserving JAK-STAT5 dominance over RAF-ERK-MAPK output. CD8 T cells from Rnf144a-/- mice showed impaired IL-2-induced effector gene expression, degranulation, and cytokine production, and CD8-intrinsic deficiency in mixed chimeras reduced antigen-specific responses and worsened weight loss and lung inflammation after influenza infection. In human influenza, RNF144A expression was reduced in severe disease, inversely correlated with an ERK-MAPK target gene signature, and discriminated severe from moderate cases with performance comparable to established severity markers. Conclusion RNF144A is an IL-2-STAT5-induced E3 ligase that enforces STAT5-dominant signaling and limits viral immunopathology. Funding Source N/A Topic Categories Immune Response Regulation: Molecular Mechanisms (IRM)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (23)

D

Dhaneshwar Kumar

E

Erin West

D

Dragana Jankovic

S

Suman Mitra

A

Alejandro Villarino

1University of Miami-Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, United States

Z

Zu-Xi Yu

National Institutes of Health

M

Marie-José Bijlmakers

King’s College London , London,

L

Lauren Brinster

5Division of Veterinary Resources, Office of Research Services, NIH, Bethesda, United States

D

Daniel Chauss

NIH

N

Nardos Cheru

National Institutes of Health

T

Tilo Freiwald

Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany

S

Sangmi Kim

King’s College London , London,

N

Nicolas Merle

NHLBI/NIH

H

Hiroyuki Nagashima

E

Estefania Nova-Lamperti

King’s College London, London, UK

B

Bingyu Yan

Stanford University

G

Gregory Weitsman

King’s College London , London,

C

Claudia Kemper

NIH

A

Arian Laurence

4UCL Hospitals NHS Trust, London, United Kingdom, London, United Kingdom

M

Majid Kazemian

J

John O’Shea

B

Behdad Afzali

S

Susan John